News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
The Danish drugmaker announced that job losses at the company will number 1,300 before the end of the year, with the majority of those already having left their roles.
A study published by graduate students at MIT showed that a synthetic mRNA-based ‘programming language’ can control protein expression in gene therapy.
UPDATE
The US FDA approval, coupled with a Humira licensing agreement, will see Sandoz’s biosimilar enter the market as of September 30, 2023.